- Conditions
- Respiratory Syncytial Virus Prevention
- Interventions
- Ad26.RSV.PreF-based Vaccine
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 60 Years to 75 Years
- Enrollment
- 755 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 13
- States / cities
- Athens, Alabama • Vestavia Hills, Alabama • Phoenix, Arizona + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2281–2304
of 10,572
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
- Interventions
- Tagraxofusp, Fludarabine, Cytarabine, Dexamethasone, Vincristine, Azacitidine, Methotrexate, Cytarabine IT, Hydrocortisone
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 29
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 25 more
- Conditions
- Tourette Syndrome
- Interventions
- AZD5213 and placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 7
- States / cities
- Orange, California • St. Petersburg, Florida • Summit, New Jersey + 4 more
- Conditions
- Hypertension
- Interventions
- Rheos® Baroreflex Hypertension System
- Device
- Lead sponsor
- CVRx, Inc.
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 591 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Inglewood, California • Los Angeles, California + 38 more
- Conditions
- Neuroendocrine Tumors in Lung
- Interventions
- Lanreotide (Autogel formulation), Placebo, Best Supportive Care
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 14
- States / cities
- Tucson, Arizona • Los Angeles, California • Denver, Colorado + 11 more
- Conditions
- Cystic Fibrosis
- Interventions
- Ceftaroline
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Cardiovascular Disease, Acute Coronary Syndrome
- Interventions
- Multifaceted Intervention with pharmacist and IVR
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 91 Years
- Enrollment
- 14,573 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2022
- U.S. locations
- 15
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Gainesville, Florida + 12 more
- Conditions
- Autism Spectrum Disorder, Developmental Disorder
- Interventions
- Not listed
- Lead sponsor
- Stemina Biomarker Discovery, Inc.
- Industry
- Eligibility
- 18 Months to 48 Months
- Enrollment
- 1,102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2023
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Sacramento, California + 5 more
- Conditions
- Covid19
- Interventions
- Fluvoxamine, Placebo
- Drug · Other
- Lead sponsor
- Susanna Naggie, MD
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 1,331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 91
- States / cities
- Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 79 more
- Conditions
- Post Prandial Distress Syndrome
- Interventions
- Placebo, 20 mg ATI 7505, 40 mg ATI 7505, 80 mg ATI 7505
- Drug
- Lead sponsor
- Procter and Gamble
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 44
- States / cities
- Chino, California • Fresno, California • Los Angeles, California + 37 more
- Conditions
- Mycobacterium Avium-intracellulare Infection, HIV Infections
- Interventions
- Azithromycin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 636 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2007
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 31 more
- Conditions
- Early Parkinson Disease
- Interventions
- aplindore MR tablets or Placebo
- Drug
- Lead sponsor
- Neurogen Corporation
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Sunnyvale, California + 22 more
- Conditions
- Iron Deficiency Anemia
- Interventions
- Ferumoxytol, FCM
- Drug
- Lead sponsor
- AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,014 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 100
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 83 more
- Conditions
- Congestive Heart Failure, Heart Failure, Heart Disease, Ischemic, Cardiovascular Diseases, Heart Failure, Systolic, Heart Failure,Congestive, Heart Arrhythmia, Heart Failure, Diastolic, Heart; Complications
- Interventions
- 3 x 10e13vg AB-1002
- Biological
- Lead sponsor
- AskBio Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 4
- States / cities
- Minneapolis, Minnesota • Cincinnati, Ohio • Columbus, Ohio + 1 more
- Conditions
- Blunt Chest Wall Trauma, Rib Fracture, Sternal Fracture
- Interventions
- Liposomal bupivacaine, 0.9% sodium chloride
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Neonatal Opiate Withdrawal Syndrome
- Interventions
- Finnegan Neonatal Abstinence Scoring Tool, Eat, Sleep, Console (ESC) care tool
- Other
- Lead sponsor
- Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program
- Network
- Eligibility
- Up to 3 Days
- Enrollment
- 1,305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 26
- States / cities
- Newark, Delaware • Tampa, Florida • Honolulu, Hawaii + 21 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- MM-121, Erlotinib
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 16 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Abatacept
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 35
- States / cities
- Huntsville, Alabama • La Jolla, California • Long Beach, California + 32 more
- Conditions
- Multiple Myeloma
- Interventions
- P-BCMA-ALLO1 CAR-T cells, Rimiducid, Methotrexate
- Biological · Drug
- Lead sponsor
- Poseida Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2042
- U.S. locations
- 23
- States / cities
- Goodyear, Arizona • San Diego, California • San Francisco, California + 19 more
- Conditions
- Irritable Bowel Syndrome With Diarrhea
- Interventions
- Ibodutant 10 mg, Placebo
- Drug
- Lead sponsor
- Menarini Group
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 535 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 65
- States / cities
- Huntsville, Alabama • Sherwood, Arizona • Little Rock, Arkansas + 56 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone
- Procedure · Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 1,400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 186
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more
- Conditions
- Acromegaly
- Interventions
- CAM2029 (octreotide subcutaneous depot), Matching placebo
- Drug
- Lead sponsor
- Camurus AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Palo Alto, California • Miami, Florida + 9 more
- Conditions
- Heart Defects, Congenital
- Interventions
- Not listed
- Lead sponsor
- Philip Moons
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 6
- States / cities
- Stanford, California • St Louis, Missouri • Omaha, Nebraska + 3 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- bevacizumab, sorafenib tosylate
- Biological · Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 204
- States / cities
- Scottsdale, Arizona • Fresno, California • Fort Collins, Colorado + 129 more